Nanotechnology in Cancer Treatment Market Positioned for Transformational Growth by 2029
'Explore how nanomedicine and targeted therapies are shaping the future of cancer care in BCC Research's global market analysis of nanotechnology in oncology.'
Boston, June 05, 2025 (GLOBE NEWSWIRE) -- As cancer prevalence continues to rise globally, nanotechnology in cancer treatment is emerging as a transformative force in oncology. Leveraging nanoscale drug delivery systems and precision-targeting techniques, companies such as AstraZeneca, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb are developing next-generation solutions to enhance therapeutic effectiveness while minimizing harm to healthy cells.
According to the report, growing cancer prevalence, rising government funding, and increased pharmaceutical R&D spending are reshaping innovation strategies across the oncology landscape. The global market is projected to grow at a CAGR of 17.4% from 2024 to 2029. As North America continues to lead market expansion and new nanomedicine applications evolve globally, stakeholders must navigate regulatory complexity, manufacturing scalability, and long-term safety considerations to harness the full potential of this technology.
Market Overview: Key Insights and Forecast
BCC Research's latest report, Nanotechnology in Cancer Treatment: Technologies and Global Markets, delivers a detailed evaluation of the evolving oncology landscape through the lens of nanomedicine. It explores how advances in nanostructured materials, targeted delivery systems, and diagnostic innovations are shaping the future of cancer treatment across major regions.
The global market was valued at $102.4 billion in 2023 and is projected to reach $265.4 billion by the end of 2029. The report delivers forward-looking insights based on current market trends and expected developments over the forecast period. It provides a strategic analysis of major segments by product type and cancer type, along with comprehensive coverage of revenue trends, regulatory frameworks, ESG priorities, technological advancements, and regional market shifts.
Market Leadership in Transition
The cancer nanomedicine space is evolving rapidly, with companies investing in product differentiation and late-stage R&D. Liposomes remain the most commercially established carriers, while polymeric nanoparticles and dendrimers are seeing increased use due to their payload capacity and tumor selectivity (Chapter 6: Market Segment Analysis).
Leading companies such as Pfizer, Novartis AG, and Jazz Pharmaceuticals are developing tailored nanocarrier systems for specific cancer indications, with a focus on breast and lung cancers. These therapies are being designed for better tumor penetration, reduced off-target toxicity and improved treatment outcomes (Chapter 7: Competitive Intelligence).
Emerging Technologies and Investment Trends
Innovation in nanomedicine is being fueled by multifunctional systems that integrate diagnosis, therapy, and monitoring. Technologies including quantum dots, cancer stem cell-targeting particles, and nanorobotics are moving closer to clinical translation, offering new capabilities in image-guided therapy and adaptive dosing.
Strong capital inflow and increased partnerships between biotech firms and research institutions are accelerating development across early and mid-stage pipelines. These trends are unlocking commercialization potential, especially in minimally invasive therapies and immuno-nanomedicine (Chapter 5: Emerging Technologies and New Developments).
Pipeline Assessment and Applications
The oncology pipeline is steadily embracing nanotechnology as a cornerstone for targeted treatment development. Companies are advancing nanoparticle-based drug carriers with enhanced tumor penetration, improved bioavailability and reduced toxicity. These innovations are driving late-stage R&D across different types of cancers, such as breast and lung cancers, leukemia and melanoma.
In parallel, there is growing interest in integrating diagnostic and therapeutic functions into single nanosystems. Platforms capable of simultaneous drug delivery and real-time tumor tracking are gaining momentum, offering the potential for adaptive dosing and early relapse detection (Chapter 6: Market Segment Analysis).
Regulatory and Access Challenges
Regulatory agencies, such as the U.S. FDA, European Medicines Agency (EMA), and other international bodies, are actively evolving frameworks to support the safe and effective approval of nanoscale cancer therapies. As manufacturers scale production, they must comply with stringent requirements related to materials handling, product traceability and lifecycle oversight (Chapter 4: Regulatory Landscape).
Challenges such as development costs, access limitations in low-income regions, and a shortage of oncology specialists trained in nanomedicine are slowing down broader adoption. Addressing these issues is essential to achieving long-term growth and equitable global impact (Chapter 3: Market Dynamics).
Strategic Outlook: The Road Ahead
With nanotechnology's role in oncology continuing to expand, companies are aligning R&D with long-term goals around innovation, clinical efficacy, and accessibility. Key companies are developing platforms that support patient-centered care, data-driven treatment personalization, and integration across diagnostic and therapeutic pathways (Chapter 2: Market Overview).
As infrastructure improves and global interest in targeted therapies grows, nanomedicine is expected to become a cornerstone of modern cancer care. Firms prioritizing early diagnosis, adaptive delivery and long-term monitoring will be best positioned to lead the market forward (Chapter 7: Competitive Intelligence).
Report Synopsis
Report Metric
Details
Base year considered
2023
Forecast period considered
2024-2029
Base year market size
$102.4 billion
Market size forecast
$265.4 billion
Growth rate
CAGR of 17.4% for the forecast period of 2024-2029
Segments covered
Product type and cancer type
Regions covered
North America, Europe, Asia-Pacific, South America, Rest of the World
Countries covered
The U.S., Canada, Mexico, Germany, France, Italy, Spain, the U.K., Austria, Sweden, Denmark, Poland, Turkey, Switzerland, the Netherlands, China, Japan, India, South Korea, Australia, Thailand, Singapore, Malaysia, New Zealand, Vietnam, Brazil, Argentina, Colombia, Paraguay, Peru, Middle East and Africa
Market drivers
Increasing prevalence of cancer cases globally.
Rise in government funding and pharmaceutical R&D spending.
Nanoparticles in cancer treatment: Advantages.
Precision targeting of cancer cells with nanomaterials.
Additional Insights:
Ultra-small and highly efficient: Nanoparticles are often smaller than a single cell; thus, it is easier for them to penetrate tumors and deliver drugs directly to cancer cells.
Stealth functionality: These particles can be engineered to "cloak" themselves from the immune system, allowing them to circulate longer within the bloodstream.
Multifunctional carriers: Nanoparticles can transport multiple drugs simultaneously, enabling combination therapies in a single delivery.
Energy-interactive: They can absorb energy from external sources, supporting their role in advanced imaging or therapeutic enhancement.
Next-level diagnostics: Nanoparticles can serve as highly sensitive imaging agents, enhancing early diagnosis and treatment precision.
Leading companies include:
AstraZeneca
Baxter
Boston Scientific Corp.
Bristol-Myers Squibb Co.
F. Hoffmann-La Roche Ltd.
Jazz Pharmaceuticals Inc.
Les Laboratoires Servier
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, providing you with the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights.
Get your copy of the report directly from BCC Research.
To request more information or complete your purchase, connect with us at info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@bccresearch.com Phone: +1 781-489-7301
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Japan Smaller Capitalization Fund, Inc. Announces Initiatives to Enhance Shareholder Value
10% Annual Rate Level Distribution Policy Conditional Tender Offer for 10% of Outstanding Shares NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Japan Smaller Capitalization Fund, Inc. (the 'Fund') (NYSE: JOF) today announced that its Board of Directors (the 'Board') has approved two initiatives aimed at addressing the Fund's trading discount. These initiatives include a level distribution plan and a conditional tender offer. The Board believes these actions reflect the Fund's ongoing commitment to enhancing shareholder value, delivering competitive performance, and providing consistent distributions to long-term shareholders. The plan (the 'Plan') includes (i) implementation of a Level Distribution Plan (the 'LDP') to pay monthly distributions at a 10% annual rate to provide more of the Fund's total return in the form of distributions, and (ii) a conditional tender offer (the 'CTO') of 10% of its outstanding shares. Level Distribution Plan The Board has approved a Level Distribution Plan under which the Fund will pay monthly distributions at an annualized rate of 10% of the Fund's Net Asset Value ('NAV') as of May 31, 2025. The Fund is declaring a monthly distribution of $0.0887 per common share for each of July, August and September. The Fund's distribution details are as follows: Record Date Ex-Dividend Date Payment Date Distribution Amount July 15, 2025 July 15, 2025 July 31, 2025 $ 0.0887 August 15, 2025 August 15, 2025 August 29, 2025 $ 0.0887 September 15, 2025 September 15, 2025 September 30, 2025 $ 0.0887 The LDP is intended to provide shareholders with a constant, though not guaranteed, fixed rate of distribution each month. In approving the LDP, the Board considered, among other factors, the potential impact of the LDP as a tool to narrow the discount to NAV at which the Fund's shares have historically traded, the Fund's ability to sustain the LDP, and the possibility that making regular distributions could enhance liquidity for common shareholders and potentially attract new investors. Distributions will be made primarily in cash but under the Fund's dividend-reinvestment plan, distributions will be made in Fund shares unless a shareholder has elected to receive cash. Shares held with a broker-dealer will receive distributions in cash. Under the LDP, distributions may be derived from any combination of: (i) net investment income, (ii) realized capital gains, and/or (iii) a return of shareholder capital. The actual composition for each fiscal year will be reported to shareholders on Form 1099-DIV after year-end. Estimates provided in any monthly notice or in this press release are not intended for tax-reporting purposes and should not be relied upon as such. The Fund cannot predict what effect, if any, the LDP will have on the market price of its shares, or whether such market price will trade at a narrower or wider discount to NAV compared to levels prior to the Plan's adoption. Conditional Tender Offer In addition to the LDP, the Board approved a Conditional Tender Offer. The Fund will launch a tender offer for 10% of its outstanding shares, provided that the Fund's shares trade at an average daily market price discount of 9% or greater to NAV during the nine-month measurement period beginning on July 1, 2025 and ending on March 31, 2026 (the 'Measurement Period'). At the end of the Measurement Period, the Fund will announce additional details about the tender offer, as appropriate. In approving the CTO, the Board considered, among other factors, that a rules-based approach gives shareholders clear, time-bounded relief if the discount persists, the complementary nature of the CTO with the LDP, the reinforcement of the Fund's commitment to shareholder-friendly capital management, and the offer of meaningful liquidity to shareholders. There can be no guarantee that these benefits will occur or that any improvement will continue. The Board may terminate or modify the parameters of the Plan at any time without prior notice to the Fund's shareholders if circumstances warrant. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund's common shares. To assist the Board in its evaluation of the LDP, the CTO, and other potential corporate actions, the Fund engaged an unaffiliated financial adviser with significant closed-end fund expertise. The professional fees associated with this limited-duration engagement will be borne by the Fund and are expected to result in a short-term increase in the Fund's expense ratio. Investment Outlook While overall earnings growth is expected to be higher in the United States, the Japanese market is expected to have growth rates comparable to the United States in most sectors besides the Industrials sector. Nomura Asset Management Co., Ltd. ('NAM') believes Return on Equity ('ROE') is on an upward trend in Japan, supported by improvements in profit margins and revenue growth. NAM expects share buybacks and dividend increases will continue to raise the financial leverage. With ongoing corporate reforms, there is a potential for ROE to rise further. Japan remains one of the most attractive markets for individual stock selection due to a lack of coverage. Continued Focus on Long-Term Value Today's announcement represents the Fund's objective to deliver competitive performance and stable distributions to shareholders. The Board and Nomura Asset Management U.S.A. Inc. ('NAM-U.S.A.') remain committed to delivering long-term value creation and addressing the interests of our shareholders. About the Fund The Fund invests primarily in the securities of smaller capitalization companies in Japan and is designed for investors seeking long-term capital appreciation. The Manager of the Fund is NAM-U.S.A., which is based in New York. NAM-U.S.A. is a subsidiary of NAM, which is one of the largest investment advisory companies in Japan in terms of assets under management and serves as the investment adviser to the Fund. Forward Looking Statements Certain information discussed in this press release may constitute forward-looking statements within the meaning of U.S. federal securities laws. Although the Fund and NAM-U.S.A. believe that the expectations reflected in such forward-looking statements are based on reasonable assumptions, the Fund and NAM-U.S.A. can give no assurance that their expectations will be achieved. Forward-looking information is subject to certain risks, trends, and uncertainties that could cause actual results to differ materially from those projected. Contact: Maria Premole 1-800-833-0018 JOFInvestorRelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Integral Metals Announces Closing of Private Placement Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 06, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | FSE: ZK9) (the 'Company' or 'Integral') is pleased to announce, further to its news releases dated February 21, 2025 and May 30, 2025, that it has closed its previously announced non-brokered private placement offering (the 'Private Placement') of common shares of the Company (the 'Common Shares') at a price of US$0.70 per Common Share, for gross proceeds of US$400,000. The Company intends to use the net proceeds of the Private Placement for expenditures on its mineral exploration properties, and for general working capital purposes. All securities issued under the Private Placement are subject to a four-month and one-day hold period. The securities issued pursuant to the Private Placement have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board Directors Paul Sparkes Chief Executive Officer 825-414-3163 info@ ABOUT INTEGRAL METALS CORP. Integral is an exploration stage company, engaged in the business of mineral exploration for critical minerals, including gallium, germanium, and rare earth elements, with the goal of contributing to the development of a domestic supply chain for these minerals. Integral holds properties in mining-friendly jurisdictions in Canada and the United States of America, including the Northwest Territories, Manitoba and Montana, where it has received regulatory support for its exploration efforts. Forward-Looking Information Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the proposed use of proceeds therefrom. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including, in respect of the forward- looking information included in this press release, assumptions regarding the future plans and strategies of the Company. Although forward-looking information is based on the reasonable assumptions of the Company's management, there can be no assurance that any forward-looking information will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among other things, that the Company's plans with respect to the use of any proceeds received from the Private Placement may change; and the risk that the Company's business prospects and priorities may change, whether as a result of unexpected events, general market and economic conditions or as a result of the Company's future exploration efforts, and that any such change may result in a re-deployment of the Company's resources and efforts in a manner divergent from the Company's current business plan or strategy. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
